Vascular-targeting agent
A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.[1]
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
- vadimezan (ASA404)
Clinical trials
Phase II : ZD6126, CA4P, plinabulin (NPI-2358)[2][3][4]
Phase III : DMXAA (ASA404).
gollark: Maybe you should install new friends.
gollark: that👏emoji👏use
gollark: Probably. But I don't think you can tell which is which unless you hardcode the positions or something.
gollark: Anyway, I haven't implemented *targeted* GPS spoofing yet, because it's not very useful and I don't control an entire dimension of GPS servers, but it might be interesting to experiment with.
gollark: It also relies on SPUDNET, which is closed-source right now because I can't be bothered to upload it somewhere.
References
- "Vascular Targeting Agents as Cancer Therapeutics" (PDF). 2004. Cite journal requires
|journal=(help) - "NPI-2358". clinicaltrials.gov.
- Monica M. Mita; et al. (2010). "Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas". Clin Cancer Res. 16 (23): 5892–5899. doi:10.1158/1078-0432.CCR-10-1096. PMID 21138873.
- Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News. 29 (8): 58.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.